Company / Cash & Equivalents
Guardant Health, Inc. Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$378.2M
FY2025
5-year range
$141.6M / $1.1B
FY2021-FY2025
Trend
-28.0%
vs FY2024
Sector context
#57 of 152
Health Care
What the data says
At $378M, Guardant Health, Inc.'s cash & equivalents ranks #57 of 152 in the Health Care sector. Cash & Equivalents has fluctuated over the past 9 years, ranging from $72M in FY2017 to $1.1B in FY2023.
Based on SEC 10-K filings.
$378M in FY2025 with a 5-year CAGR of -14.6%.
Declined from $1.1B to $378M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +38.7%
- 5-Year CAGR
- -14.6%
- 10-Year CAGR
- -
Sector benchmark
#57 of 152 in Health CareTop 37% of 152This company $378.2M Sector average $1.2B
▼
-67.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -14.6%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 28.0% year-over-year.
- Ranks #57 out of 152 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $378.2M | -28.0% |
| FY2024 | $525.5M | -53.6% |
| FY2023 | $1.1B | +700.3% |
| FY2022 | $141.6M | -71.2% |
| FY2021 | $492.2M | -40.9% |
| FY2020 | $833.0M | +481.6% |
| FY2019 | $143.2M | +1.9% |
| FY2018 | $140.5M | +94.4% |
| FY2017 | $72.3M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026